Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Testosterone undecanoate + dutasteride is a combination therapy consisting of an androgen (testosterone undecanoate) and a dual 5α-reductase inhibitor (dutasteride). Testosterone undecanoate is an ester prodrug of testosterone used for testosterone replacement therapy in adult males with primary or hypogonadotropic hypogonadism. It restores physiological levels of testosterone to treat symptoms related to deficiency such as reduced libido and muscle mass[4][5][7]. Dutasteride inhibits both type I and II 5α-reductase enzymes that convert testosterone into dihydrotestosterone (DHT), thereby reducing DHT-mediated effects like prostate enlargement[1]. The combination may be used experimentally or off-label to optimize androgen replacement while minimizing DHT-related side effects such as acne or benign prostatic hyperplasia. Dutasteride can also increase the oral bioavailability of testosterone by suppressing its conversion to DHT[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on testosterone undecanoate + dutasteride.